+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Pharmerging Market Research Report by Product (OTC Drugs and Pharmaceuticals), Indication, Distribution, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 225 Pages
  • January 2023
  • Region: Global
  • 360iResearch™
  • ID: 5635336
UP TO OFF until Mar 31st 2023
The Global Pharmerging Market size was estimated at USD 1,408.34 million in 2022, USD 1,537.84 million in 2023, and is projected to grow at a CAGR of 9.67% to reach USD 2,948.21 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Pharmerging Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Pharmerging Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Pharmerging Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Pharmerging Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Pharmerging Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Product, the market is studied across OTC Drugs and Pharmaceuticals. The Pharmaceuticals is further studied across Branded Prescription Drugs and Generic Drugs.
  • Based on Indication, the market is studied across Cancer & Autoimmune Diseases and Lifestyle Diseases.
  • Based on Distribution, the market is studied across Clinics, Drug Stores, E-Commerce, and Hospitals.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Pharmerging Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Pharmerging Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Pharmerging Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Pharmerging Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Pharmerging Market, including Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, Beckman Coulter, Inc., Bikal Ltd., CSL Behring LLC, Eli Lilly and Company, Farmson Pharmaceutical Gujarat Pvt. Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd, Johnson and Johnson, Lonza Group AG, Novartis AG, Pfizer, Inc., Rhombus Pharma Private Limited, Röchling Group, SCHOTT AG, Sun Pharmaceutical Industries Ltd., The RSA Group, and ZIM Laboratories Limited.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Pharmerging Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pharmerging Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pharmerging Market?
4. What is the competitive strategic window for opportunities in the Global Pharmerging Market?
5. What are the technology trends and regulatory frameworks in the Global Pharmerging Market?
6. What is the market share of the leading vendors in the Global Pharmerging Market?
7. What modes and strategic moves are considered suitable for entering the Global Pharmerging Market?
Frequently Asked Questions about the Global Pharmerging Market

What is the estimated value of the Global Pharmerging Market?

The Global Pharmerging Market was estimated to be valued at $1408.34 Million in 2022.

What is the growth rate of the Global Pharmerging Market?

The growth rate of the Global Pharmerging Market is 9.6%, with an estimated value of $2948.21 Million by 2030.

What is the forecasted size of the Global Pharmerging Market?

The Global Pharmerging Market is estimated to be worth $2948.21 Million by 2030.

Who are the key companies in the Global Pharmerging Market?

Key companies in the Global Pharmerging Market include Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, Beckman Coulter, Inc., Bikal Ltd., CSL Behring LLC, Eli Lilly and Company, Farmson Pharmaceutical Gujarat Pvt. Ltd and Glenmark Pharmaceuticals Ltd.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing elderly population and rising burden of chronic diseases worldwide
5.1.1.2. Rising number of private hospitals and healthcare institutes
5.1.1.3. Extensive spending on healthcare globally and growing life expectancy among people
5.1.2. Restraints
5.1.2.1. High cost of research and development and strict price control
5.1.3. Opportunities
5.1.3.1. Potential demand from targeted therapeutics or personalized medicines
5.1.3.2. Emerging adoption of pharmerging in developing economies
5.1.4. Challenges
5.1.4.1. Concerns over IP protection and socio-politics with complex government approval process
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Pharmerging Market, by Product
6.1. Introduction
6.2. OTC Drugs
6.3. Pharmaceuticals
6.4.1. Branded Prescription Drugs
6.4.2. Generic Drugs

7. Pharmerging Market, by Indication
7.1. Introduction
7.2. Cancer & Autoimmune Diseases
7.3. Lifestyle Diseases

8. Pharmerging Market, by Distribution
8.1. Introduction
8.2. Clinics
8.3. Drug Stores
8.4. E-Commerce
8.5. Hospitals

9. Americas Pharmerging Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Pharmerging Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Pharmerging Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Product Portfolio Analysis, By Key Player
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Abbott Laboratories Inc.
13.2. AstraZeneca PLC
13.3. Bayer AG
13.4. Beckman Coulter, Inc.
13.5. Bikal Ltd.
13.6. CSL Behring LLC
13.7. Eli Lilly and Company
13.8. Farmson Pharmaceutical Gujarat Pvt. Ltd
13.9. GlaxoSmithKline PLC
13.10. Glenmark Pharmaceuticals Ltd
13.11. Johnson and Johnson
13.12. Lonza Group AG
13.13. Novartis AG
13.14. Pfizer, Inc.
13.15. Rhombus Pharma Private Limited
13.16. Röchling Group
13.17. SCHOTT AG
13.18. Sun Pharmaceutical Industries Ltd.
13.19. The RSA Group
13.20. ZIM Laboratories Limited

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL PHARMERGING MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PHARMERGING MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL PHARMERGING MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL PHARMERGING MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PHARMERGING MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL PHARMERGING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL PHARMERGING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PHARMERGING MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL PHARMERGING MARKET DYNAMICS
FIGURE 11. GLOBAL PHARMERGING MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL PHARMERGING MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 13. GLOBAL PHARMERGING MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL PHARMERGING MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2030
FIGURE 15. GLOBAL PHARMERGING MARKET SIZE, BY OTC DRUGS, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL PHARMERGING MARKET SIZE, BY BRANDED PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
FIGURE 18. GLOBAL PHARMERGING MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
FIGURE 19. GLOBAL PHARMERGING MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 20. GLOBAL PHARMERGING MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL PHARMERGING MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
FIGURE 22. GLOBAL PHARMERGING MARKET SIZE, BY CANCER & AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
FIGURE 23. GLOBAL PHARMERGING MARKET SIZE, BY LIFESTYLE DISEASES, 2018-2030 (USD MILLION)
FIGURE 24. GLOBAL PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
FIGURE 25. GLOBAL PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 26. GLOBAL PHARMERGING MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION, 2030
FIGURE 27. GLOBAL PHARMERGING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
FIGURE 28. GLOBAL PHARMERGING MARKET SIZE, BY DRUG STORES , 2018-2030 (USD MILLION)
FIGURE 29. GLOBAL PHARMERGING MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
FIGURE 30. GLOBAL PHARMERGING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
FIGURE 31. AMERICAS PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 32. AMERICAS PHARMERGING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 33. AMERICAS PHARMERGING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 34. AMERICAS PHARMERGING MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 35. ARGENTINA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 36. BRAZIL PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 37. CANADA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 38. MEXICO PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 39. UNITED STATES PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. UNITED STATES PHARMERGING MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 41. UNITED STATES PHARMERGING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 42. UNITED STATES PHARMERGING MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 43. ASIA-PACIFIC PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 44. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 45. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 46. ASIA-PACIFIC PHARMERGING MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 47. AUSTRALIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 48. CHINA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. INDIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. INDONESIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. JAPAN PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. MALAYSIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. PHILIPPINES PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. SINGAPORE PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. SOUTH KOREA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. TAIWAN PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. THAILAND PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. VIETNAM PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 63. DENMARK PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 64. EGYPT PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. FINLAND PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 66. FRANCE PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 67. GERMANY PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 68. ISRAEL PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. ITALY PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. NETHERLANDS PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. NIGERIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. NORWAY PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. POLAND PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. QATAR PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. RUSSIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. SAUDI ARABIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. SOUTH AFRICA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. SPAIN PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. SWEDEN PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 80. SWITZERLAND PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 81. TURKEY PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 82. UNITED ARAB EMIRATES PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 83. UNITED KINGDOM PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 84. GLOBAL PHARMERGING MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 85. GLOBAL PHARMERGING MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 86. GLOBAL PHARMERGING MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL PHARMERGING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PHARMERGING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PHARMERGING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PHARMERGING MARKET SIZE, BY OTC DRUGS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PHARMERGING MARKET SIZE, BY OTC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PHARMERGING MARKET SIZE, BY OTC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PHARMERGING MARKET SIZE, BY BRANDED PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PHARMERGING MARKET SIZE, BY BRANDED PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PHARMERGING MARKET SIZE, BY BRANDED PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PHARMERGING MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PHARMERGING MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PHARMERGING MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PHARMERGING MARKET SIZE, BY CANCER & AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PHARMERGING MARKET SIZE, BY CANCER & AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PHARMERGING MARKET SIZE, BY CANCER & AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PHARMERGING MARKET SIZE, BY LIFESTYLE DISEASES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PHARMERGING MARKET SIZE, BY LIFESTYLE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PHARMERGING MARKET SIZE, BY LIFESTYLE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PHARMERGING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PHARMERGING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PHARMERGING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PHARMERGING MARKET SIZE, BY DRUG STORES , 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PHARMERGING MARKET SIZE, BY DRUG STORES , BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PHARMERGING MARKET SIZE, BY DRUG STORES , BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PHARMERGING MARKET SIZE, BY E-COMMERCE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PHARMERGING MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PHARMERGING MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PHARMERGING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PHARMERGING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PHARMERGING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PHARMERGING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 52. CANADA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 53. CANADA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 54. CANADA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 57. MEXICO PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. MEXICO PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. MEXICO PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES PHARMERGING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 74. CHINA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 75. CHINA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. CHINA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. CHINA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 78. INDIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 79. INDIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. INDIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. INDIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 86. JAPAN PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 87. JAPAN PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 88. JAPAN PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. JAPAN PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 102. SOUTH KOREA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 106. TAIWAN PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 107. TAIWAN PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 110. THAILAND PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 111. THAILAND PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 112. THAILAND PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. THAILAND PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 114. VIETNAM PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 115. VIETNAM PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. VIETNAM PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. VIETNAM PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 123. DENMARK PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 124. DENMARK PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 125. DENMARK PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. DENMARK PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 127. EGYPT PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 128. EGYPT PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 129. EGYPT PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. EGYPT PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 131. FINLAND PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 132. FINLAND PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 133. FINLAND PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. FINLAND PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 135. FRANCE PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 136. FRANCE PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 137. FRANCE PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. FRANCE PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 139. GERMANY PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 140. GERMANY PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 141. GERMANY PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. GERMANY PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 143. ISRAEL PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 144. ISRAEL PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 145. ISRAEL PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. ISRAEL PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 147. ITALY PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 148. ITALY PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 149. ITALY PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. ITALY PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 151. NETHERLANDS PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 152. NETHERLANDS PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 153. NETHERLANDS PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 155. NIGERIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 156. NIGERIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 157. NIGERIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. NIGERIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 159. NORWAY PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 160. NORWAY PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 161. NORWAY PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. NORWAY PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 163. POLAND PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 164. POLAND PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 165. POLAND PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. POLAND PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 167. QATAR PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 168. QATAR PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 169. QATAR PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. QATAR PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 183. SPAIN PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 184. SPAIN PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 185. SPAIN PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. SPAIN PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 187. SWEDEN PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 188. SWEDEN PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 189. SWEDEN PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. SWEDEN PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 191. SWITZERLAND PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 192. SWITZERLAND PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 193. SWITZERLAND PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 194. SWITZERLAND PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 195. TURKEY PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 196. TURKEY PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 197. TURKEY PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. TURKEY PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 207. GLOBAL PHARMERGING MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 208. GLOBAL PHARMERGING MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 209. GLOBAL PHARMERGING MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 210. GLOBAL PHARMERGING MARKET RANKING, BY KEY PLAYER, 2022
TABLE 211. GLOBAL PHARMERGING MARKET SHARE, BY KEY PLAYER, 2022
TABLE 212. GLOBAL PHARMERGING MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 213. GLOBAL PHARMERGING MARKET MERGER & ACQUISITION
TABLE 214. GLOBAL PHARMERGING MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 215. GLOBAL PHARMERGING MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 216. GLOBAL PHARMERGING MARKET INVESTMENT & FUNDING
TABLE 217. GLOBAL PHARMERGING MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 218. GLOBAL PHARMERGING MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Beckman Coulter, Inc.
  • Bikal Ltd.
  • CSL Behring LLC
  • Eli Lilly and Company
  • Farmson Pharmaceutical Gujarat Pvt. Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd
  • Johnson and Johnson
  • Lonza Group AG
  • Novartis AG
  • Pfizer, Inc.
  • Rhombus Pharma Private Limited
  • Röchling Group
  • SCHOTT AG
  • Sun Pharmaceutical Industries Ltd.
  • The RSA Group
  • ZIM Laboratories Limited

Methodology

Loading
LOADING...